Amikacin dose optimization is challenging in critically ill patients. The use of BestDose software algorithm-based drug optimization could help to achieve the recommended target concentrations (60-80 mg/L) after administration of the second dose of amikacin, associated with improved outcome. The study investigators hypothesize that 80% of patients undergoing drug dosing optimization using the BestDose software in the interventional group will reach the predefined PK/PD targets.

Inclusion Criteria:

• The patient or their legal representative must have given their free and informed consent and signed the consent form
• The patient must be a member or beneficiary of a health insurance plan
• The patient has septic shock according to the SEPSIS-3 definition in the 24 hours preceding inclusion, regardless of the source of infection
• Patient having already received a first dose of amikacin in the 22 preceding hours
• Patient with an expectation of receiving at least 2 doses of amikacin
• Patient with available amikacin therapeutic drug monitoring

Exclusion Criteria:

• The subject is participating in an interventional study that could influence the primary outcome, or is in a period of exclusion determined by a previous study
• The patient is pregnant, parturient or breastfeeding
• Patient has a contra-indication or an allergy to treatment by amikacin
• Patient is not expected to survive beyond 48 hours